U.S. Pharmacist eNewsletter
November 2022

ACIP Recommends Adding COVID-19 Vaccines to Immunization Schedules
The Advisory Committee on Immunization Practices’ (ACIP) recommendation to incorporate COVID-19 vaccines to the 2023 childhood and adult immunization schedule just “streamlines” the process, according to the CDC. Republican attorney generals from a dozen states strongly object and want CDC director Rochelle Wolensky to reject the suggestion, as well as the ACIP’s recommendation to include the vaccine in the Vaccines for Children Program. Read more.


GSK RSV Vaccine for Older Adults Highly Effective
The widespread outbreak of respiratory syncytial virus (RSV) among children in the United States does not bode well for older adults, who tend to have more severe cases when they contract it. A vaccine candidate from GSK is showing promise for protecting that group in the future, however, stating 94.1% vaccine efficacy against lower respiratory tract disease for adults aged 60 years and older. Read more.


Shingrix Cost-Effective for Younger Immunocompromised Patients
The FDA expanded the use of Shingrix, a recombinant zoster vaccine, to immunocompromised adults aged 19 to 49 years last year, noting that immunocompromised patients experience a higher incidence of herpes zoster and related complications. Shingrix is highly cost-effective for immunocompromised patients. Find out what an analysis published in Value Health said about cost versus quality-of-life years.

Connect With U.S. Pharmacist
Facebook Twitter USP Google AppUSP Itunes App
Advertisement Advertisement